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P21-ACTIVATED KINASE-1 SIGNALING REGULATES TRANSCRIPTION OF
TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR
Beatriz Sánchez-Solana1, Mona Motwani1, Da-Qiang Li1, Jeyanthy Eswaran2 and Rakesh Kumar1*
1

Department of Biochemistry and Molecular Biology, 2McCormick Proteomic and Genomic Center,
School of Medicine and Health Sciences, George Washington University, Washington DC 20037, USA.
*Correspondence: bcmrxk@gwu.edu
Running title: PAK1 making in-roads into TF Pathway
Key words: PAK1, Signaling, Transcription, Tissue Factor, Tissue Factor pathway inhibitor

Results: PAK1 stimulates and represses the
expression of TF and TFPI, respectively, and
promotes procoagulant activity.
Conclusion: PAK1 is identified as an important
player in the coagulation processes.
Significance: Targeting PAK1 might lead to a
novel therapeutic strategy in the control of
coagulation.
ABSTRACT
Tissue factor (TF) is a cell-surface glycoprotein
responsible for initiating the coagulation
cascade. Besides its role in homeostasis, studies
have shown the implication of TF in embryonic
development, cancer related events, and
inflammation via coagulation-dependent and independent (signaling) mechanisms. Tissue
factor pathway inhibitor (TFPI) plays an
important role in regulating TF-initiated blood
coagulation.
Therefore,
transcriptional
regulation of TF expression and its physiologic
inhibitor TFPI, would allow us to understand
the critical step that control many different
processes. From a gene profiling study aimed to
identify differentially regulated genes between
wild type (WT) and p21-activated kinase 1-null
(PAK1-KO) mouse embryonic fibroblasts
(MEFs), we found TF and TFPI are
differentially expressed in the PAK1-KO MEFs
in comparison to wild-type MEFs. Based on
these findings, we further investigated in the
present study the transcriptional regulation of
TF and TFPI by PAK1, a serine/threonine

kinase. We found that PAK1/c-Jun complex
stimulates the transcription of TF and
consequently,
its
procoagulant
activity.
Moreover, PAK1 negatively regulates the
expression of TFPI and thus, additionally,
contributes to increased TF activity. For the
first time, this study implicates PAK1 in
coagulation processes, through its dual
transcriptional regulation of TF and its
inhibitor.
INTRODUCTION
Tissue factor (TF) (also known as F3,
coagulation factor III or thromboplastin), a 47KDa transmembrane glycoprotein and the primary
initiator of the coagulation cascade (1), plays a
critical role in homeostasis and thrombosis (2). It
functions as a high-affinity receptor for the serine
proteases factors VII and VIIa. The resulting TFVIIa complex activates both factors IX and X
leading to thrombin generation and fibrin
formation (1). TF-induced coagulation is regulated
by a specific inhibitor termed Tissue factor
pathway inhibitor (TFPI). The mechanism of
inhibition by TFPI involves its binding first to
factor Xa and then to the VIIa/ TF complex (1).
In the last few years, it has become evident that
TF is involved in various other (patho)
physiological processes apart from homeostasis,
such as embryonic development, transmision of
signals, promotion of cell migration, adhesion,
tumor initiation, growth, and inflammation (3).
Concomitantly, TFPI, the physiologic inhibitor of
TF, has also been widely implicated in the
regulation of those non-homeostatic functions of
TF (4). TF is essential for the normal embryonic
development and its absence could lead to a
defective vessel development and embryonic death
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Background: TF and TFPI, two primary
components of the coagulation cascade, play
important roles in non-homeostatic and
pathological events.

2
in mice (5). The expression of TF is deregulated in
many cancers, and this up-regulation is often
linked with aggressive malignancies (6) and
increased tumor growth (7). Moreover, expression
of TF amplifies the inflammatory reaction in
patients with sepsis (8,9).

The PAKs are serine/threonine kinases that
were originally identified as binding partners and
downstream effectors of Cdc42 and Rac1 in actin
reorganization and cell migration (11). PAK1, the
best-characterized member of the PAK family, is
activated by the p21ras-related proteins Cdc42 and
Rac1 (11), but also by a wide variety of
extracellular signals (12) which promote PAK1’s
auto-phosphorylation and stimulation of its kinase
activity (13). PAK1 kinase activity has been
implicated in a wide variety of cellular processes,
including, cell motility, survival and proliferation,
morphogenesis, cytoskeleton remodeling, and
transcription (14). In addition to its wellcharacterized kinase activity, the PAK1 pathway
also affects nuclear events in a profound manner
(15-17) and also regulates the transcription of
target gene chromatin (18-20).
During a previous gene profiling study that
includes wild-type (WT) and knock-out PAK1
(PAK1-KO) mouse embryonic fibroblasts (MEFs),
we identified TF and TFPI to be down- and upregulated, respectively, in the PAK1-KO MEFs in
comparison to its wild type controls (RK,
unpublished data), suggesting that PAK1 might
regulate the expression of TF and TFPI. Given the
involvement of TF, and TFPI, in several
pathological and physiological events, the present
study was undertaken to investigate the genomic
regulation of TF and TFPI by PAK1 signaling. To
date, nothing is known about the regulation of TF

EXPERIMENTAL PROCEDURES
Cell culture, Antibodies and Reagents. HeLa,
HEK 293T and MDA-MB-231 cells were obtained
from American Type Culture collection (ATCC),
and cultured in Dulbecco’s modified Eagle’s
medium/F12 supplemented with 10% fetal bovine
serum and 1X antibiotic-antimycotic solution in a
humidified 5% CO2 at 37°C. PAK1 WT and KO
mouse embryonic fibroblasts (MEFs) have been
described earlier (21). Sources of antibodies were
as follows: mouse anti-phospho-PAK1 (Thr 212)
(Sigma-Aldrich, St. Louis, MO), Rabbit antiPAK1 (Bethyl laboratories, Montgomery, TX),
mouse anti-Tissue Factor (10H10) (Novus
Biologicals, Littleton, CO), mouse anti-vinculin
(Sigma-Aldrich, St. Louis, MO), rabbit anti-c-JUN
(Santa Cruz Biotechnologies, Santa Cruz, CA),
mouse anti-myc Tag (9B11) (Cell Signaling
Technology, Danvers, MA), and mouse anti-Flag
M2 (Sigma-Aldrich, St. Louis, MO). Normal
mouse IgG, and rabbit IgG were from SigmaAldrich (St. Louis, MO). All primary antibodies
were used as according to manufacturer’s
instructions. Horseradish peroxidase-conjugated
secondary antibodies were from GE Healthcare
(Piscataway,
NJ),
and
enhanced
chemiluminescence (ECL) reagents were from
Amersham Biosciences (Piscataway, NJ). The
blocking antibody for human Tissue factor TF85G9 was a generous gift of Dr. James H.
Morrissey (University of Illinois).
Expression vectors, recombinant proteins, siRNAs,
and transfections. Expression vectors encoding
PAK1-myc, PAK1 T423E, and PAK1 K229R
were generously provided by Jonathan Chernoff
(Fox Chase Cancer Center, Philadelphia, PA) and
have been previously described (22), pCDNA3.1-
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TF contributes to pathologies by activation of
the coagulation cascade (proteolysis dependent
signaling) as well as by coagulation-independent
(proteolysis independent) signaling events via the
cytoplasmic domain of TF (3,10). Thus, TF might
not only function as the initiator of coagulation but
also as a transmembrane signaling receptor which
regulates angiogenesis, tumor growth, metastasis,
and inflammation. Therefore, understanding the
transcriptional regulation of TF expression and its
inhibitor, TFPI, would appear to be a critical step
in the control of many different processes.

expression by PAK1 in cancer cells. We
discovered, for the first time, that PAK1 signaling
stimulates and inhibits the transcription of TF and
TFPI, respectively, and modulates the coagulation
process.

3

Microarray Gene Expression Assays and Analysis.
Microarray gene expression assays and data
analysis have been described previously (26). The
datasets of differentially expressed genes between
PAK1 WT and KO MEFs were analyzed using
Ingenuity Pathway Analysis to discover
relationships between the genes as well as their
association with various processes and disorders
(Motwani et al, unpublished). The Fisher’s exact
test was used to identify significant functions and
pathways represented within the respective
datasets.
Quantitative Real Time PCR (qPCR). Total RNA
was isolated from cultured cells using TRIzol
reagent (Invitrogen, Carlsbad, CA) according to

the manufacturer’s protocol, and two micrograms
of extracted RNA was converted to cDNA using
the SuperScriptTM III First-Strand Synthesis
System for RT-PCR (Invitrogen, Carlsbad, CA).
The resultant cDNA was subjected to qPCR by
using the iQTM SYBR® Green Supermix (BioRad Laboratories, Hercules, CA) on an iCycler
iQ™ Real-Time PCR Detection System (Bio-Rad
Laboratories). The values for specific genes were
normalized to human actin or mouse 18S
housekeeping controls. Mean values are displayed
± standard deviations. The primers used were:
hACTIN_F: 5’-TCC CTG GAG AAG AGC TAC
GA-3’, hACTIN_R: 5’-GTA CTT GCG CTC
AGG AGG AG-3’, hTF_F: 5’-GCC CGG TAG
AGT GTA TGG GCC AG-3’, hTF_R: 5’-GCT
CTG CCC CAC TCC TGC CTT-3’, hTFPI_F: 5’AGT ATG GTG GAT GCC TGG GCA ATA-3’,
hTFPI_R: 5’- ACC TGG AAA CCA TTC GGA
CCA TCT-3’, m18S_F: 5’-CCG GAG CTA GGA
ATA ATG GA-3’, m18S_R: 5’-CCC TCT TAA
TCA TGG CCT CA-3’, mTF_F:5’-AGA ACA
CCC CGT CGC GCT TG-3’, mTF_R: GCT CTC
CGC AAC AGT GCC GT-3’, mTFPI_F: 5’- TGT
TGC TTA GCC TTG TTC CCG AGT-3’, and
mTFPI_R: TGC TTT GCA TGG ACC ATC ATC
TGC-3’. All qPCR primers were synthesized in
Sigma-Aldrich (St. Louis, MO).
Western Blot and Immunoprecipitation. Protein
extracts were prepared by lysing the cells in the
RIPA buffer containing 50 mM Tris-HCl, pH 7.4,
1% Nonidet P-40, 0.25% sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1×protease inhibitor
cocktail (Roche Applied Science, Indianapolis,
IN), and 1× phosphatase inhibitor cocktail I and II
(Sigma-Aldrich, St. Louis, MO), and protein
concentrations were determined using Bio-Rad
DC Protein Assay reagents (Bio-Rad Laboratories,
Hercules, CA). Cell extracts were then resolved by
SDS-PAGE,
transferred
to
nitrocellulose
membranes, and incubated with the indicated
antibodies. Detections were performed using the
ECL reagents. For immunoprecipitation (IP)
analysis, total 1 mg of protein materials was
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PAK1, and GST-PAK1 have been described
previously (23). pcDNA-c-JUN-Flag (c-JUN-Flag)
and GST-c-JUN have been used previously (24).
The dominant negative mutant of c-JUN was a
generous gift from Dr. Powell H. Brown (National
Cancer Institute, NIH, Rockville, Maryland, MD)
and has already been described (25). All GST
recombinant proteins were expressed in E. coli
strain BL21 (DE3) (Stratagene, La Jolla, CA) and
subsequently purified using the Glutathione
Sepharose 4B batch method (GE Healthcare,
Piscataway, NJ). In vitro translation was
performed using The TNT® Quick Coupled
Transcription/Translation Systems (Promega,
Madison, WI). Plasmid transfections were carried
out using FuGENE HD Transfection Reagent
(Roche Applied Science, Indianapolis, IN)
according to manufacturer’s instructions. When
needed, after 24h of transfection, cells were serum
starved for another 24 hours, before serum
stimulation for the indicated times. Specific
siRNAs targeting human PAK1 or control siRNAs
were obtained from Cell Signaling Technology
(Danvers, MA). The transfection of siRNA was
performed twice at 24-hour intervals with
Oligofectamine TM reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. 24
hours after the second round of transfection, cells
were serum starved for 24 hours, before serum
stimulation for the indicated times.

4

GST pull-down assays. The GST pull-down assays
were performed by incubating equal amounts of
GST or GST fusion protein immobilized to
glutathione-Sepharose beads with in-vitro
translated 35S-labeled protein, in a 400 µl reaction
volume. The mixtures were incubated for 2h at 4
°C and washed three to six times with NP40 lysis
buffer. Bound proteins were eluted with 2x SDS
buffer, separated by SDS-PAGE and visualized by
autoradiography. The transferred protein on the
blot was visualized using Ponceau S stain.
Chromatin Immunoprecipitation (ChIP) and reChIP assays. The ChIP assays were performed as
described previously (27). Briefly, approximately
106 cells were treated with 1% formaldehyde (final
concentration) for 10 min at 37°C to cross-link
histones to DNA and washed twice with
phosphate-buffered saline containing protease
inhibitors cocktail. Cells were lysed by sonication
and immunoprecipitated with specific antibodies.
The immunoprecipitates were washed, the DNA
was eluted off the beads, and purified DNA
(phenol-chloroform extraction) was subjected to
PCR. PCR primers for ChIP assays for TF and
TFPI promoters are provided in supplemental
Tables 1 and 2, respectively. For re-ChIP assays,
the first ChIP using a PAK1 antibody (Bethyl
laboratories) was followed by a second ChIP using

a c-JUN antibody (Santa Cruz biotechnology).
Quantification of the bands amplified by PCR was
done using ImageJ software.
Electrophoretic Mobility Shift Assay. Nuclear
extracts were prepared using a Nonidet P-40 lysis
method (28). EMSA for the binding of different
transcription factors was performed using the
annealed
and
[γ-32P]
ATP
end-labeled
oligonucleotides in a 20-µl reaction mixture for 15
min at 20 °C.
Samples were run on a
nondenaturing 5% polyacryalmide gel and imaged
by autoradiography. Supershift EMSAs were
performed by incubating the nuclear extracts with
2µg of either the PAK1 (Bethyl laboratories,
Montgomery, TX) or the c-JUN (Santa Cruz
Biotechnology, Santa Cruz, CA) antibody for 1
hour before the addition of the radiolabeled
oligonucleotides. Oligonucleotides used are listed
in supplemental Table 3.
Tissue Factor procoagulant activity (PCA) assay.
TF activity, measured as the amount of FXa
generated, was determined using the AssaySense
Human TF Chromogenic Activity Assay Kit
(AssayPro) with minor modifications, according to
Drake TA et al (29). Cells were detached by brief
exposure to Trypsin-EDTA, washed three times
with DMEM/F12 and resuspended in DMEM/F12
at 4 x 105 cells/ml. For blocking cell-surface
expressed TF, anti-TF mAb TF8-5G9 (10µg/ml)
was incubated with 1ml of the corresponding
intact cell suspensions for 15 min at 37 °C, washed
three times with DMEM/F12 and divided into two
equal portions. One portion was resuspended in
Hepes-saline buffer (25mM Hepes, 0.85% NaCl,
pH 7.4) and kept at 4 °C before assay of intact cell
surface TF activity. The other portion was lysed
by freezing the cell suspension at -70 °C for 15
min and solubilization with 15mM octyl-β-Dglucopyranoside at 37 °C for 15 minutes for assay
of total
TF procoagulant activity. Identical
aliquots of intact (cell surface TF PCA) and lysed
cells (total TF PCA) were assayed, following the
manufacturer’s recommendations, and the amount
of FXa generated was determined by reading the
absorbance at 405nm every 2 minute for 20
minutes, using a kinetic 96 well microplate reader
(Synergy-H1 Hybrid Reader, Biotek).
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incubated with 1 µg of primary antibody overnight
at 4 ° C on a rocket platform, followed by
incubation with total 50 µl of protein A/G PLUSagarose (Santa Cruz Biotechnology, Santa Cruz,
CA) or Trueblot IP beads (eBioscience, San
Diego, CA) for 2 h at 4 °C. The
immunoprecipitates
were
collected
by
centrifugation in a microcentrifuge at 6000 rpm
for 5 min. The supernatant was discarded,
whereupon the pellet was washed with Nonidet P40 buffer (NP40 lysis buffer) (50 mM Tris-HCl,
pH 8.0, 0.5 % Nonidet P-40, 10 % Glycerol, 150
mM NaCl, 2 mM MgCl2 , and 1 mM EDTA), with
protease inhibitors for three to five times and then
dissolved in a sample buffer for SDS-PAGE.

5

RESULTS AND DISCUSSION
PAK1 up regulates the expression of Tissue
factor

In the microarray analysis, TF, the primary
initiator of the coagulation cascade, was
remarkably found to be differentially expressed
between both cell lines. The expression of TF was
2.53-fold down-regulated in the PAK1-KO
compared to wild-type MEFs (Table 1). Consistent
with the above data, RT-quantitative PCR
confirmed that TF expression was down-regulated
in the PAK1 KO MEFs as compared with its wildtype counterparts (Fig. 1A), positioning TF as a
potential downstream target of PAK1. Through its
impact on the coagulation cascade and cellular
signaling, TF acts as an important regulator of
vascular development, several cancer-related
processes,
such
as
hypercoagulability,
angiogenesis and metastasis, and inflammation
(3). Therefore, the knowledge of its transcriptional
regulation will be of great scientific interest.
A previous study already implicated PAK1 in
the regulation of TF expression in PASMCs (30).
These authors observed that PAK1 is involved in
thrombin signaling in PASMC and regulates the
expression of TF by activating p38MAPK, PDK1
and PKB, and thus, PAK1 could play a role in
vascular remodeling. Given the stablished
connection
between
malignancy
and
hypercoagulant states (31) and PAK1’s role in
malignant processes (32), as well as the linkage of
TF with cancer related processes (6,33), the
possible role of PAK1 as a modulator of

PAK1 is required for TF up regulation by serum
Since the induction of TF by serum has been
well described (34), to further demonstrate the
implication of PAK1 in the regulation of TF
expression by serum, we examined the effect of
PAK1 down regulation conditions on TF
expression. As shown in Fig. 2A, PAK1 down
regulation by siRNA transfection in HeLa cells
compromised the ability of serum to stimulate TF
protein as compared to cells transfected with a
control siRNA. The induction of TF mRNA
expression was also analyzed in wild-type and
PAK1-KO MEFs (Fig. 2B). The results show that
the serum induction of TF mRNA observed in the
wild-type MEFs was almost completely abolished
in PAK1-KO MEFs, highlighting the significance
of PAK1 in the regulation of TF expression.
We next examined whether the kinase activity
of PAK1 is essential for the regulation of TF
expression. To test this, we analyzed the effect of
a dominant-negative K229R and catalytically
active T423E PAK1 mutants (22,35) on the
expression of TF by serum (Fig. 2C). Transient
transfection of HeLa cells with the catalytically
active T423E PAK1 mutant resulted in a superior
stimulation of TF protein and mRNA by serum as
compared to the control cells (Fig. 2C). On the
other hand, cells expressing the kinase-dead
K229R PAK1, partially suppressed the ability of
serum to stimulate TF protein and mRNA
expression levels (Fig.
2C). These results
demonstrate the significance of PAK1 expression
and activity in the induction of TF expression by
serum.
PAK1 recruitment onto TF promoter
The previously observed nuclear localization of
PAK1 (18), as well as its already reported
modulatory effect in the transcription of some
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Microarray gene profiling study that includes
wild-type (WT) and PAK1- knockout (KO) mouse
embryonic fibroblasts (MEFs) was performed to
identify the new genes or pathways that are
influenced by PAK1 (RK, unpublished data).
When the statistically significant differentially
expressing genes were studied using Ingenuity
Pathway Analysis, a total of 16 genes assigned to
thrombosis were differentially expressed in
between wild-type and PAK1-KO MEFs (Table
1). These findings raise a new interesting line of
research and for the first time; introduce PAK1 as
a possible new regulatory player in thrombosis.

thrombosis in cancer cells was viewed of high
interest for a more in depth study. To date, nothing
is known about the regulation of TF by PAK1 in
cancer cells. Further studies in the human
epithelial cancer cell lines, such as HeLa and
MDA-MB-231, demonstrated that the serum
induction of PAK1 activity induced up regulation
of TF protein as well as mRNA levels (Fig. 1B
and C), suggesting a role of PAK1 in the
regulation of TF expression.

6
genes, such as nuclear factor of activated T-cell
(NFAT1) and the phosphofructokinase-muscle
isoform (PFKM) (18), prompted us to investigate
the direct genomic regulation of TF transcription
by PAK1 in cancer cells.

Involvement of c-JUN transcription factor in
PAK1- mediated TF up regulation
Since PAK1 lacks transcriptional activity but is
able to induce TF expression, we next
hypothesized that PAK1 might be co-recruited to
the TF promoter along with a transcription factor,
which could be responsible for the direct
stimulation of TF transcription. For this reason, we
next performed a sequence analysis of the TF
promoter-PAK1 interacting regions (regions 3-4,
see Fig. 3B) using the Promo 3.0 software (36) to
identify the putative binding sites for transcription
factors that might be responsible for the PAK1mediated stimulation of TF transcription. The
complete list of the resulting transcription factor
binding sites is presented in Table 2. We found
that TF promoter harbors binding sites for some
transcription factors already involved in cell
growth, proliferation and cancer related signaling
events. These included TCF-4E, GATA-1, TFII-I,

To assess the above possibility, we examined
the direct recruitment of these transcription factors
to the TF promoter by electrophoretic mobility
shift assay (EMSA) (Fig. 4A). To this end, we
designed
double-stranded
oligonucleotides,
containing the binding site(s) for each
transcription factor(s), that were radiolabeled, and
the binding of each transcription factor was
analyzed using nuclear extracts from control and
serum-stimulated HeLa cells. After electrophoresis
and autoradiography, we detected the formation of
DNA-protein complexes with the oligonucleotides
containing binding sites for AP-1/c-JUN as well as
TFII-I binding site b among the tested
transcription factors (Fig. 4A). In addition, the
observed complex was induced in serumstimulated HeLa cells compared to non-stimulated
cells,
only
when
using
the
specific
oligonucleotides for AP-1/c-JUN binding site (Fig.
4A), suggesting that PAK1-serum stimulated
signaling uses AP-1/c-JUN to induce TF
transcription. Accordingly, results from Fig. 4B,
using nuclear extracts from control and serumstimulated HeLa (left panel) or MDA-MB-231
cells (right panel) revealed that the formation of
AP-1/c-JUN - DNA complex(s) at the TF
promoter was completely abolished using an
oligonucleotide containing the putative binding
site mutated, confirming the presence of AP-1/cJUN. In addition, the observed complex could be
highly inhibited, especially under serum-induced
conditions, in the presence of an anti-c-JUN
antibody, as well as in the presence of an antiPAK1 antibody, but not with a control
immunoglobulin IgG antibody, suggesting the coexistence of PAK1- and c-JUN/DNA complex(s).
However, the presence of an anti-c-JUN antibody
failed to exhibit the appearance of a super-shifted
band, probably due to inefficient blocking of the
recognition site for c-JUN in the DNA sequence
and/or antibody-specific reasons.
To gain a deeper insight into the molecular
mechanism involved in c-JUN regulation of TF
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Therefore, we examined the recruitment of
PAK1 in the promoter of TF using a ChIP- based
promoter walk assay. To this end, cross-linked
chromatin
from
HeLa
cells
was
immunoprecipitated with an anti-PAK1 antibody
or IgG, and then PCR-amplified using primers
designed against about every 400-base pair (bp)
region of the TF promoter (Fig. 3A). Results from
Fig. 3B show that PAK1 was recruited to the TF
promoter at a region encompassing -666 to -1529
bp from the transcription start site (TSS). In an
attempt to narrow down the region of the TF
promoter in which PAK1 was recruited, regions 3
and 4, which are positive for PAK1 recruitment,
were subdivided further into two smaller regions,
of about 200 bp each. New primers encompassing
these regions were designed, and the same purified
eluted DNA was PCR-amplified using these
primers (Fig. 3C). We discovered that PAK1 was
indeed recruited to the regions 3.2 to 4.2, but not
to the region 3.1 (Fig. 3C). Our results indicate,
for the first time, that PAK1 is able to specifically
bind to the TF promoter region, demonstrating that
TF is a target of PAK1.

PXR-1: RXR-alpha, c-ETS-1, or AP-1/c-JUN (3742). Similarly, the involvement of both PAK1 and
TF in such processes has been well stablished
(13,33). Therefore the above mentioned
transcription factors appear to be good candidates
for PAK1-mediated TF transcriptional up
regulation.

7
expression, we next analyzed the in vivo
recruitment of c-JUN to the TF promoter by
chromatin immunoprecipitation (ChIP), using
cross-linked chromatin from HeLa cells. We found
the recruitment of c-JUN onto the region 3 of the
TF promoter (Fig 4C). This is in agreement with
the Promo 3.0 sequence analysis of the TF
promoter-PAK1 interacting DNA region, which
indicates this region comprises the binding site for
c-JUN.

Results from Fig. 4B, as well as the fact that cJUN is recruited to the TF promoter region 3 (R3)
(Fig. 4C), suggest that both PAK1 and c-JUN
could be co recruited at the same region onto the
TF promoter. To determine whether the PAK1/cJUN complex associates to the same region onto
the TF promoter, a sequential double-ChIP
analysis using the indicated antibodies was
performed. We found that indeed, PAK1 and cJUN are co-recruited onto the c-JUN-TF promoter
interacting region R3 (Fig. 4D), demonstrating the

To further demonstrate the importance of cJUN in PAK1-mediated TF up regulation, HeLa
cells were co-transfected with the catalytically
active mutant of PAK1 (T423E), and with a
dominant negative mutant of c-JUN (TAM 67)
that can repress its transcriptional activity (25).
The cells were induced with serum for the
indicated times, prior to the analysis of TF
expression by qPCR. The presence of a dominant
negative mutant of c-JUN partially suppressed the
ability of the catalytically active mutant of PAK1
to stimulate TF mRNA expression after serum
induction (Fig. 4E), confirming the involvement of
c-JUN in the regulation of TF expression by
PAK1.
PAK1 physically interacts with c-JUN.
It has been previously reported that PAK1
activates JNK, resulting in the phosphorylation
and activation of c-JUN (47). However, our
findings that PAK1 and c-JUN are co recruited
onto the TF promoter raises the possibility of
physical interaction between them. To test this
notion, HEK293T cells were co-transfected with
expression vectors encoding Flag-tagged c-JUN
and Myc-tagged PAK1, and protein extracts were
subjected
to
the
sequential
immunoprecipitation/Western blot (WB) analysis.
Results from Fig. 5A show that, indeed,
exogenously expressed Flag-c-JUN but not control
IgG could be coimmunoprecipitated with MycPAK1, suggesting that the two proteins interact in
vivo. In addition, similar interaction was observed
between PAK1 and c-JUN at the endogenous
protein level in HeLa cells (Fig.
5B). To
determine whether PAK1 directly binds to c-JUN,
we next performed in vitro GST pull- down assays
using 35S-labeled, in vitro-translated c-JUN protein
and full-length GST-PAK1 fusion protein, as well
as 35S-labeled, in vitro-translated PAK1 protein
and full-length GST-c-JUN fusion protein, and
found that 35S-labeled c-JUN and 35S-labeled
PAK1 strongly bound to GST-PAK1 and GST-cJUN proteins respectively (Fig. 5C and D). These
findings demonstrate that PAK1 physically
associates with c-JUN both in vivo and in vitro. It
is noteworthy that PAK2 is also shown to bind and
phosphorylate c-JUN modulating its activity (48).
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The regulation of TF gene expression by c-JUN
has been demonstrated in human monocytic and
endothelial cells (43,44), as well as in cultured
fibroblasts (45). However, the binding region of cJUN reported in these studies (located at a region
around -200 to -220 bp, relative positions to the
transcription start site (43-45)) is different from
the one detected in the present study (-1450 bp,
relative to the transcription start site). On the other
hand, a previous report located elements required
for serum and phorbol miristate acetate (PMA)
induction of TF promoter in HeLa cells in a region
between -96 and +121 bp, from a total region
analyzed of 300 bp relative to the transcription
start site (46). This region lacks any AP1/c-JUN
binding site, but it is possible, however, that cJUN could account for the induction of TF gene
transcription by serum in HeLa cells in a different
region than the analyzed in the previous study (46)
as compared to results obtained in the present
study. The apparent controversy between different
results could be explained by the fact that the TF
gene is expressed in a cell type-specific manner
(29). Moreover, our results suggest that not only
the expression of TF appears to be mediated by
distinct regions of the TF promoter in different cell
types, but also, the induction in response of
different stimuli can be mediated by distinct
regions of the promoter in the same cell type.

co recruitment of both proteins onto the TF
promoter.
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Given the similarity in the phosphorylation
recognition motifs of PAK1 and PAK2, these
results suggest that PAK1 interaction with c-JUN
promotes its transcriptional activation and leads to
induction of TF expression.
PAK1 stimulation regulates the procoagulant
activity of Tissue factor.

The corresponding intact cell suspensions were
incubated with either control or anti-TF antibody
for 15 min at 37°C and then washed to remove
unbound antibody before cells were either lysed
(for assay of total TF activity) or collected (for
assay of cell surface TF activity), and the TF
activity measured. As previously reported (49),
intact HeLa cells expressed very little cell surface
TF activity compared to the total TF activity in
disrupted cells (data not shown). In addition, the
presence of the TF blocking antibody was able to
reduce <5% of the total activity (data not shown),
thus indicating that the majority of TF in HeLa
cells was expressed intracellularly, which is in
agreement with previous reports (49). The
presence of an intracellular pool may be
particularly important because it is likely to be
protected from extracellular inhibitors of TF.
Furthermore, previous studies have found that a
substantial portion of TF is not active on the
surface of unperturbed cells, and have suggested
that much of the TF is encrypted on the cell
surface (50). Therefore, to further verify the
implication of TF in the generation of FXa, the
experiment was performed in the absence of FVII.
This approach completely blocked all the activity

In order to gain insight into the ability of PAK1
to induce TF procoagulant activity, we monitored
the ability of the endogenously expressed TF to
enhance the specific proteolytic activation of FX
to FXa during the whole assay (Fig. 6A and B).
This is achieved through the constant annotation
of the change in absorbance of the released
chromophore pNA at 405 nm. A clear increase in
the TF procoagulant activity during the whole
analysis was observed after serum treatment of the
control and T423E PAK1 expressing cells, and
this induction was more notable in cells expressing
the catalytically active form of PAK1, T423E (Fig.
6A ). On the contrary, serum was unable to further
induce any TF activity in cells expressing the
dominant negative PAK1 mutant (K229R) (Fig.
6B).
Active TF was determined from the standard
curves generated, at two different time points (10
and 20 minutes), using known concentrations of a
recombinant human TF preparation, and expressed
as pM of TF per number of cells (Fig. 6C). We
found that control cells as well as catalytically
active mutant PAK1 (T423E) cells showed a
higher level of active TF after serum stimulation.
Moreover, cells expressing the catalytically active
PAK1 (T423E), showed even a higher level of
active TF in serum stimulation conditions, as
compared to control cells. However, the levels of
active TF remained without any change in cells
transiently transfected with the kinase dead mutant
of PAK1 (K229R) (Fig. 6C), thus highlighting the
implication of PAK1 activation in the control of
TF coagulation activity. Together, these results
implicate PAK1 signaling acts as a modulator of
the coagulation protease cascade, by playing a role
in the modulation of TF ability to activate FX.
PAK1 recruitment onto TFPI promoter and
modulation of its expression
The above results demonstrate the significance
of PAK1 signaling in the coagulation cascade
triggered by TF. Interestingly, the natural inhibitor
of the TF-mediated coagulation, Tissue Factor
Pathway inhibitor (TFPI), was also found to be
differentially expressed between wild-type and
PAK1-KO MEFs (Table 1). PAK1-KO MEFs
showed a 3.46 fold up regulation of TFPI
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To investigate the possibility of PAK1
involvement in the coagulation cascade triggered
by TF, we analyzed the TF activity, as means of its
ability to activate Factor X (FX) to FXa. The
amount of FXa generated was quantitated using a
highly specific FXa substrate releasing a yellow
para-nitroaniline (pNA) chromophore. The change
in absorbance of the pNA at 405 nm is directly
proportional to the TF enzymatic activity. HeLa
cells transiently over-expressing the dominantnegative K229R or catalytically active T423E
PAK1 mutants, or control cells (empty vector)
stimulated or not with serum for 3 hours were used
for these experiments (Fig. 6).

(data not shown), thus demonstrating that the
results obtained were entirely due to TF activity.

9
compared to wild-type MEFs, suggesting a
possible negative regulation of TFPI expression by
PAK1.

We next investigated the importance of PAK1
kinase activity in the regulation of TFPI
expression. We analyzed the effect of the
dominant-negative K229R and catalytically active
T423E PAK1 mutants (22,35) on TFPI mRNA
expression after serum induction (Fig. 7E). As
expected, serum induction of cells overexpressing
a kinase-dead PAK1 mutant (K229R) resulted in a
progressive up regulation of TFPI mRNA
expression, but no stimulation of TFPI mRNA
levels was observed in those cells expressing the
catalytically active PAK1 mutant (T423E).
Results from Fig. 7 D and E suggest that PAK1
expression and activation negatively regulates
TFPI expression at the transcriptional level. To
further strengthen this hypothesis, we next
explored the recruitment of PAK1 to the promoter
of TFPI using a ChIP-based promoter walk assay
in cross-linked chromatin from HeLa cells
immunoprecipitated with an anti-PAK1 antibody
or IgG control antibody. A region of the human

Balanced levels of TF and TFPI are essential to
maintain normal homeostasis. In this regard, the
ability of PAK1 to up regulate TF expression, and
down regulate TFPI expression places PAK1 as a
new key molecule involved in the deregulation of
normal homeostasis. In agreement with the results
presented here, previous work from Diebold et al
demonstrates the expression of PAK1 in the media
of remodeled pulmonary vessels from patients
with pulmonary vasculopathy and its implication
in vascular remodeling by thrombin signaling in
pulmonary artery smooth muscle cells (PASMCs)
(52). Future studies, with the use of smooth
muscle cells are guaranteed in order to better
elucidate the role of PAK1 in thrombosis. From
another point of view, given the role of PAK1 as a
central signaling transducer and the emerging
functions of TF, as well as of TFPI in different
signaling events apart from homeostasis (53,54),
our findings open a new transcriptional regulatory
axis that could be highly relevant not only in
coagulation, physiological signaling pathways, but
also in several malignant processes.
In summary, we provide here a novel
regulatory mechanism of TF expression and
procoagulant activity in epithelial cancer cells by
PAK1-c-JUN complex. Furthermore, PAK1 is
able to bind to the TFPI promoter, and negatively
regulates its expression, presumably releasing the
inhibition of the TF-FVIIa complex from TFPI,
and in-turn, contributing to a hypercoagulant state
(Fig. 7H). Our working model provides a novel
function for PAK1 in the control of coagulation
processes, suggesting that the control of PAK1
activity may act as a new and exciting potential
therapeutic strategy.
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RT-quantitative PCR analysis confirmed the up
regulation of TFPI in the PAK1- KO cells as
compared with its wild-type counterparts (Fig.
7A). Furthermore, serum induction of PAK1 in
HeLa and MDA-MB-231 human cell lines led to
down regulation of TFPI mRNA expression (Fig.
7B and C, respectively), suggesting that PAK1 can
negatively modulate the expression of TFPI.
Similar to TF, the expression of TFPI has also
been reported to be modulated by serum (51).
Hence, further studies were designed to
demonstrate the significance of PAK1 signaling in
the down regulation of TFPI expression. To this
end, we analyzed the expression of TFPI mRNA
in PAK1-KO MEFs or wild-type MEFs under
serum stimulation conditions. We found a down
regulation of TFPI mRNA levels by serum
stimulation in the wild-type MEFs, and this down
regulation was not only compromised in the serum
stimulated PAK1-KO MEFs, but we observed
instead a transient up regulation of TFPI mRNA
expression levels in these cells, suggesting that
PAK1 may be essentially involved in the
repression of TFPI expression.

TFPI promoter of approximately 1700 base pairs
(+25 to -1653 bp relative positions from the TSS)
was analyzed by PCR using primers designed
about each 400 bp (Fig. 7F). As shown in Fig. 7G,
ChIP results showed the recruitment of PAK1 onto
the TFPI promoter to a region encompassing -798
to -1198 bp from the TSS, named Region 3 (R3).
In summary, results from Fig. 7 demonstrates, for
the first time, that PAK1 is recruited to the TFPI
promoter and that PAK1 acts as a negative
modulator of TFPI expression.
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Figure legends.

Figure 2. PAK1 is required for the upregulation of Tissue factor by serum. A. Western blot analysis
of PAK1 and Tissue factor (TF) in HeLa cells transiently transfected with an siRNA against PAK1
(siPAK1) or an siRNA control (siC) induced with serum for the indicated times (in minutes). The
expression of vinculin was used as a loading control. The numbers below the panels (in grey) indicate the
densitometric values corresponding to the quantification of the bands detected by autorradiography. A
representative Western blot, from a total of three independent experiments, is shown. B. RT-qPCR
analysis of Tissue factor (TF) mRNA in WT and PAK1 KO mouse embryonic fibroblast (MEFs) cells
induced with serum for the indicated times (in minutes). The relative mRNA expression levels are
represented; mouse 18S expression was used to normalize the values. Each value represents the mean ±
S.E. of three independent experiments.*, P<0.005; **, P < 0.001, versus non stimulated WT MEFs. #,
P<0.005; ##, P < 0.001, versus serum stimulated WT MEFs. C. Western blot (upper panel) and RT-qPCR
analysis (lower panel) in HeLa cells transiently transfected with the catalytically active (T423E), kinase
dead (K229R) PAK1 mutants or with the empty vector (CTRL) induced with serum for the indicated
times. C, upper panel. Cell lysates were blotted with PAK1 and Tissue factor (TF) antibodies. The
expression of vinculin was used as a loading control. The numbers below the panels (in grey) indicate the
densitometric values corresponding to the quantification of the bands detected by autorradiography. A
representative Western blot, from a total of three independent experiments, is shown. C, lower panel.
Total mRNA was analyzed for the expression of Tissue factor (TF) mRNA by RT-qPCR. The relative
mRNA expression levels are represented; actin expression was used to normalize the values. Each value
represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001, versus non
stimulated control (CTRL) cells. #, P<0.005 versus serum stimulated control (CTRL) cells. min: minutes.
Figure 3. PAK1 is recruited to the promoter of Tissue Factor. A. Schematic representation of the
promoter of Tissue factor, showing the regions (R) analyzed. B, C. ChIP analysis of the recruitment of
PAK1 on the hTF promoter in HeLa cells. Negative (Neg) controls, without DNA, are shown for each
region amplified. Input represents around 1-10% of the total immunoprecipitated DNA. The histogram on
the right show the densitometric analysis of the bands amplified by PCR. The intensity of the bands
amplified in the samples immunoprecipitated with IgG was used as the reference and assigned the value
1. Ab: antibody.
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Figure 1. PAK1 upregulates Tissue factor expression. A. Microarray RT-qPCR validation of Tissue
factor (TF) mRNA expression in the WT and PAK1KO MEFs. The relative mRNA expression levels are
represented; mouse 18S was used to normalize the values. **, P < 0.001, versus WT MEFs. B and C.
The expression of Tissue factor protein (upper panel) and mRNA (lower panel) levels was analyzed after
serum induction for the indicated times (minutes) in HeLa (B) and MDA-MB-231 cells (C). B and C,
upper panel. Western blot using phospho-PAK1 (pPAK1), PAK1 and Tissue factor (TF) antibodies. The
expression of vinculin was used as a loading control. The numbers below the panels (in grey) indicate the
densitometric values corresponding to the quantification of the bands detected by autorradiography. A
representative Western blot, from a total of three independent experiments, is shown. B and C, lower
panel. Total mRNA from HeLa (B) or MDA-MB-231 (C) cells induced with serum for the indicated
times was analyzed for the expression of Tissue factor (TF) mRNA by RT-qPCR. The relative mRNA
expression levels are represented; actin expression was used to normalize the values. Each value
represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001 in serum
stimulated cells compared to non stimulated cells. min: minutes.
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Figure 5. PAK1 interacts physically with c-JUN. A. HEK 293T cells were co-transfected with
expression vectors encoding Flag-c-JUN and Myc-PAK1. Protein extracts were immunoprecipitated (IP)
with control IgG or an anti- Myc antibody, and were immunoblotted (WB) with the indicated antibodies.
The input represents around 10% of the total amount of protein used for the immunoprecipitation. B.
Nuclear protein extracts from HeLa cells were immunoprecipitated with an anti-PAK1 or anti-c-JUN
antibodies, followed by Western blotting (WB) using the indicated antibodies. C. In vitro transcribedtranslated c-JUN protein (35S-labeled) was incubated with GST or GST-PAK1 constructs. Bound proteins
were separated and analyzed by SDS-PAGE and autoradiography. D. In vitro transcribed-translated
PAK1 protein (35S-labeled) was incubated with GST or GST-c-JUN constructs. Bound proteins were
separated and analyzed by SDS-PAGE and autoradiography. The lower panels in C and D are Ponceau Sstained blots showing either GST-PAK1 or GST-c-JUN and GST. The asterisk (*) denotes the presence
of the GST-PAK1 or GST-c-JUN fusion proteins.
Figure 6. PAK1 activation regulates the procoagulant activity of Tissue factor. A, B. Monitorization
of Tissue factor (TF) activity in cell lysates from control HeLa cells (CTRL), or cells transiently
overexpressing the catalytically active (T423E)(A) and kinase deficient (K229R) (B) PAK1 mutants
under serum starvation/ induction conditions. The change in absorbance at 405 nm of the released paranitroaniline (pNA) chromofore, which is directly proportional to the TF enzymatic activity, was recorded
each 2 minutes for 20 minutes. The average and standard deviation from three independent experiments is
shown. Arrows indicate the time points in which the amount of active Tissue Factor was calculated in C.
C. Amount of active endogenous Tissue Factor (TF) expressed in lysates from control HeLa cells
(CTRL), or cells transiently overexpressing the catalytically active (T423E) and kinase deficient (K229R)
mutants of PAK1 under serum starvation/ induction conditions. Values were extrapolated from a standard
curve generated with different known concentrations of a recombinant human Tissue Factor preparation,
and expressed as pM of TF per 105 cells. The average and standard deviation from triplicates is shown. *,
P<0.005; **, P < 0.001 versus non stimulated cells. #, P<0.005 in T423E PAK1 mutant cells (T423E)
compared to control HeLa cells (CTRL) under serum stimulation conditions. min: minutes.
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Figure 4. c-JUN is involved in the PAK1-mediated regulation of Tissue Factor expression. A.
EMSA analysis of the binding of GATA-1, PXR-1:RXR-alpha, TCF-4E, AP1/c-JUN, c-ETS, and TFII-I
transcription factors to the human Tissue Factor promoter using radiolabeled oligonucleotides
encompassing the predicted consensus binding sites and nuclear extracts from HeLa cells under serum
starvation/ induction conditions. a and b denote different binding sites predicted for the annotated
transcription factor. c: control lane without nuclear lysate.+/-: nuclear lysate from HeLa cells induced or
not with serum, respectively. B. EMSA analysis of c-JUN and PAK1 binding to the human Tissue factor
promoter using the wild-type (WT) and mutant (MUT) oligonucleotides encompassing c-JUN consensus
binding sites using HeLa (left panel) or MDA-MB-231 (right panel) nuclear lysates prepared from cells
stimulated or not with serum. c: control lane without nuclear lysate. +/-: nuclear lysate from HeLa cells
induced or not with serum, respectively . Ab: Antibody. C. ChIP analysis of the recruitment of c-JUN onto
the hTF promoter in HeLa cells. R: region. D. Double ChIP analysis of the recruitment of PAK1-c-JUN
complex onto the Tissue factor chromatin region 1 (R1) and 3 (R3) in HeLa cells. The first ChIP was
carried out with an anti-PAK1 antibody followed by second ChIP with anti-c-JUN antibody. Negative
(Neg) controls, without DNA, are shown for each region amplified by ChIP. Input represents around 110% of the immunoprecipitated DNA. E. RT-qPCR analysis of Tissue Factor (TF) mRNA expression in
HeLa cells transiently overexpressing the catalytically active mutant of PAK1 (T423E), and the dominant
negative mutant of c-JUN (TAM 67) after serum stimulation for the indicated times (in minutes). The
relative mRNA expression levels are represented; actin expression was used to normalize the values. Each
value represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001, versus non
stimulated T423E PAK1 mutant (T423E) cells. #, P<0.005 versus serum stimulated T423E PAK1 mutant
(T423E) cells. min: minutes.
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Figure 7. PAK1 downregulates TFPI mRNA expression by its direct recruitment to the TFPI
promoter. A. RT-qPCR validation of Tissue factor pathway inhibitor (TFPI) mRNA expression in the
WT and PAK1 KO MEFs. The relative mRNA expression levels are represented; mouse 18S was used to
normalize the values. **, P < 0.001, versus WT MEFs. B and C. RT-qPCR analysis of Tissue factor
pathway inhibitor (TFPI) mRNA in HeLa (B) and MDA-MB-231 (C) cells after serum induction for the
indicated times (in minutes). The relative mRNA expression levels are represented; actin expression was
used to normalize the values. Each value represents the mean ± S.E. of three independent experiments.
min: minutes. *, P<0.005; **, P < 0.001 in serum stimulated cells compared to non stimulated cells. D.
RT-qPCR analysis of Tissue factor pathway inhibitor (TFPI) mRNA in WT and PAK1 KO mouse
embryonic fibroblast (MEFs) cells induced with serum for the indicated times. The relative mRNA
expression levels are represented; mouse 18s expression was used to normalize the values. Each value
represents the mean ± S.E. of three independent experiments. *, P<0.005; **, P < 0.001 in serum
stimulated cells compared to non stimulated cells. min: minutes. E. RT-qPCR analysis of Tissue factor
pathway inhibitor (TFPI) mRNA in HeLa cells transiently transfected with the catalytically active
(T423E), kinase dead (K229R) PAK1 mutants or with the empty vector (CTRL) induced with serum for
the indicated times. The relative mRNA expression levels are represented; actin expression was used to
normalize the values. Each value represents the mean ± S.E. of three independent experiments. *,
P<0.005; **, P < 0.001, versus non stimulated control (CTRL) cells. #, P<0.005; ##, P<0.001, versus
serum stimulated control (CTRL) cells. min: minutes. F. Schematic representation of the promoter of
Tissue factor pathway inhibitor, showing the regions (R) analyzed by ChIP. G. ChIP analysis of the
recruitment of PAK1 on the hTFPI promoter in HeLa cells. Negative (Neg) controls, without DNA, are
shown for each region amplified. Input represents around 1-10% of the total immunoprecipitated
DNA.Ab: antibody. H. Schematic representation of TF and TFPI regulation by PAK1. Serum stimulation
of PAK1 results in the upregulation of TF, by the co-recruitment of PAK1 and c-JUN onto the human TF
promoter. The upregulation of TF expression by PAK1 is followed by an induction of the procoagulant
activity of TF. At the same time, serum stimulation of PAK1 results in the downregulation of TFPI
expression by the co-recruitment of PAK1 and a yet unknown transcription factor onto the TFPI
promoter, thereby releasing the TF-FVIIa coagulation-initiation complex from its inhibition, and possibly
contributing to a hypercoagulant state.

17
Table 1. List of the down-regulated or up-regulated genes, involved in thrombosis, in the PAK1 knockout MEFs compared to its wild-type controls.
Fold
change
7.86

NM_011058|NM_001083316

Pdgfra

5.04

down

NM_009255

Serpine2

3.27

down

NM_010171
NM_008610
NM_031168

F3
Mmp2
Il6

2.53
2.51
2.42

down
down
down

NM_009506

Vegfc

2.37

down

NM_001110504|NM_007600
NM_011576

Capn1
Tfpi

4.88
3.46

up
up

NM_011198

Ptgs2

3.26

up

NM_010217
NM_008873
NM_009931
NM_019521

Ctgf
Plau
Col4a1
Gas6

2.70
2.25
2.08
2.02

up
up
up
up

NM_011057

Pdgfb

2.01

up

NM_008969

Ptgs1

2.01

up

Regulation
down

Gene description
thrombomodulin
platelet derived growth factor
receptor, alpha polypeptide
serine (or cysteine) peptidase
inhibitor, clade E, member 2
coagulation factor III
matrix metallopeptidase 2
interleukin 6
vascular endothelial growth factor
C
calpain 1
tissue factor pathway inhibitor
prostaglandin-endoperoxide
synthase 2
connective tissue growth factor
plasminogen activator, urokinase
collagen, type IV, alpha 1
growth arrest specific 6
platelet derived growth factor, B
polypeptide
prostaglandin-endoperoxide
synthase 1
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NM_009378

Gene
symbol
Thbd

refseq
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Table 2. Complete list of the Transcription factor binding sites predicted in the Tissue factor promoterPAK1 interacting region using Promo 3.0 software analysis. The transcription factors selected for
electrophoretic mobility shift assay (EMSA) are highlighted.

TRANSCRIPTION Number of
Activator/repressor
FACTOR
sites

2

Activator

GR [T05076]
GR-beta [T01920]
GR-alpha [T00337]

1
14
7

Activator/repressor
Activator/repressor
Activator/repressor

XBP-1 [T00902]

1

Activator

AP-2alphaA
[T00035]
C/EBPbeta[T00581]
HOXD9 [T01424]
HOXD10 [T01425]

4

Activator/repressor

19
2
2

Repressor
Activator
Activator

TFIID [T00820]

1

Activator

FOXP3 [T04280]

2

Repressor

YY1 [T00915]

2

Activator/repressor

GATA-1 [T00306]

2

Activator

TFII-I [T00824]

2

Activator/repressor

HNF-1A [T00368]

1

Activator

PXR-1:RXR-alpha
[T05671]

1

Activator/repressor

c-Ets-1 [T00112]

1

Activator/repressor

STAT4 [T01577]

1

Activator

AP-1 [T00029]

1

c-Jun [T00133]
LEF-1 [T02905]

1
1

Associated with reduced survival in ERbreast cancer cells
Positive regulation of epithelial cell
proliferation
Regulation of genes controlling
development,
metabolism and immune response
Immune system and cellular stress
response
Differentiation and development of neural
crestal cells
Inflammatory and immune responses
Morphogenesis
Differentiation and limb development
Basal transcription and transcription
initiation
Immune system responses
Proposed core component of chromatin
remodellin complexes
Platelet agregation and formation
Cell growth and cancer
Growth factor signaling. Implications in
cancer
Liver-specific genes. Glucose homeostasis
Assembly of functional peroxisomes
(PXR-1).
Mediator of retinoids (RXR-alpha)
Stem cell development, cell senescence
and death, and tumorigenesis
Mediation of cellular responses to IL-12 in
T-lymphocites
Signaling molecule for TH1 differentiation

Activator

Differentiation, proliferation and apoptosis

Activator

Wnt signaling
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TCF-4E [T02878]

Function
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